Effect of Fingolimod for treatment of COVID-19-induced cytokine storm

Phase 3

Recruiting

Conditions: Condition 1: Coronavirus (COVID-19)-induced pneumonia. Condition 2: Coronavirus (COVID-19)-induced pneumonia.
COVID-19, virus identified
U07.1
J12.8

Registration Number: IRCT20200317046797N2

Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 40

Inclusion Criteria

Moderate to severe 2019-nCoV-infected
18 Years to 80 Years
Patients or authorized family members volunteered to participate in this study and signed informed consent
Both genders

Exclusion Criteria

Patient with elevated liver enzymes (3 times)
Patients who are participating in other drug clinical trials
Patients with active pulmonary tuberculosis
Patients with definite bacterial and fungal infections
Pregnant or lactating women
Patient with active thrombotic event

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement of the symptoms of lung, pulmonary infiltrates. Timepoint: At baseline (before intervention) and 2 day after drug administration. Method of measurement: Lung CT scan.;Decreased hospitalization period. Timepoint: At baseline and discharge time. Method of measurement: counting the hospitalization days.;Mortality rate. Timepoint: At baseline and discharge time. Method of measurement: observation.;Need for intubation. Timepoint: period of hospitalization. Method of measurement: observation or reading of hospitalized documents.

Secondary Outcome Measures